A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients

Phase 1CompletedNCT01688531

Galderma R&D38 enrolled

Overview

Exploratory, international, multi-centre, randomized, investigator blinded study in acne

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

SINGLE

Enrollment

Conditions

Acne

Interventions

CD0271 0.1%/CD1579 2.5% gelDRUG

one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months

CD0271 0.1%/CD1579 2.5% gel vehicleDRUG

one application (pea-sized amount according to the labelling) on a half-face, 5 to 7 days for 6 months

Eligibility

Sex: ALLMin age: 18 YearsMax age: 35 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female subjects aged 18 to 35 years inclusive * Subjects with active, moderate acne Exclusion Criteria: * The subject has a secondary acne form (chloracne, drug-induced acne, etc.) (Screening) * The subject has a severity of acne that is not amenable to treatment with CD0271-CD1579 (Screening)

Locations (3)

Galderma Investigational site

Windsor, Ontario, Canada

Galderma Investigational site

Montreal, Quebec, Canada

Galderma Investigational site

Nantes, France

Outcomes

Primary Outcomes

Description and documentation of acne lesions

Time frame: over 6 months

Secondary Outcomes

Treatment effect on acne lesions

Time frame: over 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.